Beyond Air Inc. has highlighted the publication of an independent peer-reviewed study in Intensive Care Medicine Experimental that examines the antimicrobial properties of high-dose inhaled nitric oxide (iNO) across multiple respiratory infection applications. The comprehensive review synthesized findings from 27 clinical studies, documenting the compound's multimodal antimicrobial activity and potential efficacy in treating hospital-acquired pneumonia, COVID-19, bronchiolitis, and nontuberculous mycobacteria infections.
The published research provides clinical validation for Beyond Air's ongoing development programs centered on high-dose iNO therapy. The study's findings encompass multiple infection pathways and disease indications, suggesting potential therapeutic applications across several respiratory conditions that currently lack effective treatment options or face emerging resistance challenges.
Beyond Air's executive leadership indicated that the publication supports the company's clinical development strategy and may facilitate advancement of high-dose iNO candidates through regulatory pathways. The independent peer review process represents a significant milestone in establishing the scientific foundation for the therapeutic approach.